Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 12/20 | 0.44 |
| ▸ | ACACA | Q13085 | 5/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.41 |
| ▸ | LIPE | Q05469 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GRN | P28799 | 1/20 | 0.39 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8023066 | 0.80 | RAB9A (0.44) | LIPEKDM4E | |
| SCHEMBL23361429 | 0.80 | KDM4E (0.58) | OPRM1OPRD1OPRK1LIPEKDM4E | |
| SCHEMBL868628 | 0.79 | LMNA (0.57) | KDM4ELMNA | |
| SCHEMBL4596357 | 0.79 | LMNA (0.59) | ACACBLIPEKDM4ELMNA | |
| SCHEMBL8025063 | 0.79 | PDE4B (0.49) | OPRM1OPRD1OPRK1KDM4ELMNA | |
| SCHEMBL8026494 | 0.77 | L3MBTL1 (0.44) | LIPEKDM4E | |
| SCHEMBL4536002 | 0.77 | LTA4H (0.45) | ACACBOPRM1OPRD1OPRK1GRN | |
| SCHEMBL4597944 | 0.74 | GAA (0.62) | LMNA | |
| Acetic Acid SCHEMBL29276422 | 0.74 | NNMT (0.47) | ACACBKDM4ELMNA | |
| SCHEMBL4597520 | 0.74 | OPRM1 (0.52) | OPRM1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1924265-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | Genzyme Corporation (US) | 2008-05-28 | — | — | EP | disclosed |
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
| WO-2007022371-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066624-A1 | Chemokine receptor binding compounds | CCR5, CCR4, CCR1 | ACACB 1442/4885ACACA 1135/4885OPRM1 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.